Alkermes (ALKS) Misses Q2 EPS by 13c, Post FY11 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ALKS Hot Sheet
Price: $45.89 +0.44%
Financial Fact:
Selling, general and administrative: 11.1M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Selling, general and administrative: 11.1M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Alkermes (NASDAQ: ALKS) reported Q2 EPS of ($0.22), $0.13 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $67.71 million.
Alkermes sees FY2012 EPS of $-0.89-$-0.78, versus prior guidance of $-0.47-$0.38 and the consensus of $-0.21. Alkermes sees FY2012 revenue of $350-$380 million, versus prior guidance of $205-$229 million and the consensus of $377.32 million.
Alkermes sees FY2012 EPS of $-0.89-$-0.78, versus prior guidance of $-0.47-$0.38 and the consensus of $-0.21. Alkermes sees FY2012 revenue of $350-$380 million, versus prior guidance of $205-$229 million and the consensus of $377.32 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alkermes (ALKS) PT Raised to $50 at H.C. Wainwright
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
